**Trader consensus prices an 89% implied probability on "No" for a hantavirus vaccine in 2026, driven by the absence of any candidates in late-stage clinical trials amid the virus's low incidence and complex antigenic diversity across strains.** Official CDC and WHO guidance confirms no licensed vaccines or specific antivirals exist, with hantavirus pulmonary syndrome reporting just dozens of U.S. cases annually despite 30-50% fatality rates. Recent catalysts include a May 2026 cruise ship outbreak (eight WHO-confirmed/suspected cases, three deaths) spurring preclinical advances—like University of Bath's stable antigen and U.S. Army's completed Phase 1 DNA vaccine—but experts note full approval timelines exceed a decade without Warp Speed-scale acceleration. ClinicalTrials.gov lists only early-phase studies (e.g., Phase 1 Andes virus DNA vaccine), with no Phase 3 underway; upcoming trial initiations offer little path to 2026 licensure.
Polymarket 데이터를 참조하는 실험적 AI 생성 요약입니다. 이것은 거래 조언이 아니며 이 마켓의 정산에 영향을 미치지 않습니다. · 업데이트Hantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
$82,136 거래량
$82,136 거래량
2026.12.31
$82,136 거래량
$82,136 거래량
2026.12.31
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.**Trader consensus prices an 89% implied probability on "No" for a hantavirus vaccine in 2026, driven by the absence of any candidates in late-stage clinical trials amid the virus's low incidence and complex antigenic diversity across strains.** Official CDC and WHO guidance confirms no licensed vaccines or specific antivirals exist, with hantavirus pulmonary syndrome reporting just dozens of U.S. cases annually despite 30-50% fatality rates. Recent catalysts include a May 2026 cruise ship outbreak (eight WHO-confirmed/suspected cases, three deaths) spurring preclinical advances—like University of Bath's stable antigen and U.S. Army's completed Phase 1 DNA vaccine—but experts note full approval timelines exceed a decade without Warp Speed-scale acceleration. ClinicalTrials.gov lists only early-phase studies (e.g., Phase 1 Andes virus DNA vaccine), with no Phase 3 underway; upcoming trial initiations offer little path to 2026 licensure.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
마켓 개설일: May 4, 2026, 10:39 AM ET
거래량
$82,136종료일
2026.12.31마켓 개설일
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.**Trader consensus prices an 89% implied probability on "No" for a hantavirus vaccine in 2026, driven by the absence of any candidates in late-stage clinical trials amid the virus's low incidence and complex antigenic diversity across strains.** Official CDC and WHO guidance confirms no licensed vaccines or specific antivirals exist, with hantavirus pulmonary syndrome reporting just dozens of U.S. cases annually despite 30-50% fatality rates. Recent catalysts include a May 2026 cruise ship outbreak (eight WHO-confirmed/suspected cases, three deaths) spurring preclinical advances—like University of Bath's stable antigen and U.S. Army's completed Phase 1 DNA vaccine—but experts note full approval timelines exceed a decade without Warp Speed-scale acceleration. ClinicalTrials.gov lists only early-phase studies (e.g., Phase 1 Andes virus DNA vaccine), with no Phase 3 underway; upcoming trial initiations offer little path to 2026 licensure.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
거래량
$82,136종료일
2026.12.31마켓 개설일
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...**Trader consensus prices an 89% implied probability on "No" for a hantavirus vaccine in 2026, driven by the absence of any candidates in late-stage clinical trials amid the virus's low incidence and complex antigenic diversity across strains.** Official CDC and WHO guidance confirms no licensed vaccines or specific antivirals exist, with hantavirus pulmonary syndrome reporting just dozens of U.S. cases annually despite 30-50% fatality rates. Recent catalysts include a May 2026 cruise ship outbreak (eight WHO-confirmed/suspected cases, three deaths) spurring preclinical advances—like University of Bath's stable antigen and U.S. Army's completed Phase 1 DNA vaccine—but experts note full approval timelines exceed a decade without Warp Speed-scale acceleration. ClinicalTrials.gov lists only early-phase studies (e.g., Phase 1 Andes virus DNA vaccine), with no Phase 3 underway; upcoming trial initiations offer little path to 2026 licensure.
Polymarket 데이터를 참조하는 실험적 AI 생성 요약입니다. 이것은 거래 조언이 아니며 이 마켓의 정산에 영향을 미치지 않습니다. · 업데이트
외부 링크에 주의하세요.
외부 링크에 주의하세요.
자주 묻는 질문